Gilead Sciences, Inc. (GILD) DCF Valuation

Gilead Sciences, Inc. (GILD) DCF Valuation
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Gilead Sciences, Inc. (GILD) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Engineered for accuracy, our [GILD] DCF Calculator enables you to evaluate Gilead Sciences, Inc. valuation using actual financial data, providing complete flexibility to modify all key parameters for improved forecasts.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019
AY2
2020
AY3
2021
AY4
2022
AY5
2023
FY1
2024
FY2
2025
FY3
2026
FY4
2027
FY5
2028
Revenue 22,449.0 24,689.0 27,305.0 27,281.0 27,116.0 25,725.2 24,405.7 23,153.9 21,966.4 20,839.7
Revenue Growth, % 0 9.98 10.6 -0.08789599 -0.60482 -5.13 -5.13 -5.13 -5.13 -5.13
EBITDA 7,559.0 4,133.0 11,329.0 8,852.0 10,496.0 8,389.4 7,959.1 7,550.9 7,163.6 6,796.2
EBITDA, % 33.67 16.74 41.49 32.45 38.71 32.61 32.61 32.61 32.61 32.61
Depreciation 1,404.0 1,480.0 2,050.0 2,103.0 2,693.0 1,924.1 1,825.4 1,731.8 1,642.9 1,558.7
Depreciation, % 6.25 5.99 7.51 7.71 9.93 7.48 7.48 7.48 7.48 7.48
EBIT 6,155.0 2,653.0 9,279.0 6,749.0 7,803.0 6,465.3 6,133.7 5,819.1 5,520.6 5,237.5
EBIT, % 27.42 10.75 33.98 24.74 28.78 25.13 25.13 25.13 25.13 25.13
Total Cash 25,840.0 7,910.0 7,829.0 7,630.0 7,264.0 11,085.9 10,517.3 9,977.9 9,466.1 8,980.6
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 3,582.0 4,892.0 4,493.0 4,777.0 4,660.0
Account Receivables, % 15.96 19.81 16.45 17.51 17.19
Inventories 2,067.0 3,014.0 2,734.0 2,820.0 1,787.0 2,487.9 2,360.3 2,239.2 2,124.4 2,015.4
Inventories, % 9.21 12.21 10.01 10.34 6.59 9.67 9.67 9.67 9.67 9.67
Accounts Payable 713.0 844.0 705.0 905.0 550.0 747.2 708.9 672.5 638.0 605.3
Accounts Payable, % 3.18 3.42 2.58 3.32 2.03 2.9 2.9 2.9 2.9 2.9
Capital Expenditure -825.0 -650.0 -579.0 -728.0 -585.0 -681.9 -647.0 -613.8 -582.3 -552.4
Capital Expenditure, % -3.67 -2.63 -2.12 -2.67 -2.16 -2.65 -2.65 -2.65 -2.65 -2.65
Tax Rate, % 17.41 17.41 17.41 17.41 17.41 17.41 17.41 17.41 17.41 17.41
EBITAT 6,424.6 141.5 6,977.7 5,330.5 6,444.7 4,423.7 4,196.8 3,981.5 3,777.3 3,583.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 2,067.6 -1,154.5 8,988.7 6,535.5 9,347.7 5,349.9 5,693.8 5,401.8 5,124.7 4,861.9
WACC, % 5.23 4.5 5.04 5.07 5.09 4.98 4.98 4.98 4.98 4.98
PV UFCF
SUM PV UFCF 22,961.1
Long Term Growth Rate, % 3.00
Free cash flow (T + 1) 5,008
Terminal Value 252,332
Present Terminal Value 197,854
Enterprise Value 220,815
Net Debt 18,902
Equity Value 201,913
Diluted Shares Outstanding, MM 1,258
Equity Value Per Share 160.50

What You Will Get

  • Real GILD Financial Data: Pre-filled with Gilead Sciences’ historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Gilead Sciences’ intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Gilead Sciences, Inc. (GILD).
  • WACC Calculator: Comes with a pre-built Weighted Average Cost of Capital sheet featuring customizable inputs specific to GILD.
  • Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates to fit Gilead's financial outlook.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Gilead Sciences, Inc. (GILD).
  • Dashboard and Visualizations: Graphical outputs present key valuation metrics for straightforward analysis of GILD.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review Gilead Sciences, Inc.'s pre-filled financial data and forecasts.
  3. Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Watch the DCF model update instantly as you adjust your assumptions.
  5. Step 5: Analyze the outputs and leverage the results for investment decisions.

Why Choose This Calculator for Gilead Sciences, Inc. (GILD)?

  • Comprehensive Tool: Features DCF, WACC, and financial ratio analyses all in one solution.
  • Customizable Inputs: Modify yellow-highlighted cells to explore different scenarios.
  • Detailed Insights: Automatically computes Gilead's intrinsic value and Net Present Value.
  • Preloaded Data: Historical and projected data provide reliable starting points.
  • Professional Quality: Perfect for financial analysts, investors, and business consultants.

Who Should Use Gilead Sciences, Inc. (GILD) Products?

  • Healthcare Investors: Make informed investment choices with comprehensive market analysis tools.
  • Pharmaceutical Analysts: Streamline your research with detailed reports and data on drug development.
  • Consultants: Easily customize presentations for clients focusing on biopharmaceutical strategies.
  • Life Sciences Enthusiasts: Enhance your knowledge of biotechnology and pharmaceutical innovations through case studies.
  • Educators and Students: Utilize as a resource for real-world applications in healthcare and pharmaceutical education.

What the Template Contains

  • Pre-Filled DCF Model: Gilead Sciences’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Gilead’s profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.